ZAHIL, a subsidiary of Zydus Lifesciences, acquires a stake in Mylab Discovery Solutions

Zydus Lifesciences, a discovery-driven global life sciences company, has acquired a 6.5% stake in Mylab Discovery Solutions from Rising Sun Holdings, an investment company owned by Adar Poonawalla, through its wholly owned subsidiary Zydus Animal Health &Investments Limited (ZAHIL). The acquisition represents a shared vision to transform healthcare by combining the two companies' therapeutic expertise in human formulations and diagnostic capabilities.

The transaction is subject to customary closing conditions being met. "The research and development capabilities of Zydus in therapeutics, combined with the R&D expertise of Mylab in diagnostics, along with Zydus' last-mile access, have the potential to bring decentralised healthcare solutions to the masses," said Hasmukh Rawal, managing director of Mylab. By focusing on decentralised healthcare, companies can provide timely and accurate diagnostics, effective treatments, and localised healthcare services to individuals, healthcare providers, and communities."

"It is the first time in India that a pharmaceutical company, a diagnostic company, and a vaccine manufacturer join forces," said Sujit Jain, director of Strategy at Mylab Discovery Solutions. "I am confident that this collaboration will change the way diseases are diagnosed, treated, and prevented." The synergy through this collaboration will open up new possibilities for advancements in precision medicine, personalized treatments, and preventive care. It will foster innovation, promote cross-disciplinary collaboration, and pave the way for new discoveries and therapies.